GVS advice lasmiditan (Rayvow®) for the treatment of migraine
The National Health Care Institute has assessed whether lasmiditan (Rayvow®) can be included in the Medicine Reimbursement System (GVS). A medicinal product is eligible for reimbursement once it is included in the GVS. Lasmiditan can be used for the treatment of migraine. The National Health Care Institute advises the Minister for Health, Welfare and Sport (VWS) to include lasmiditan (Rayvow®) on List 1A of the GVS in cluster 0N02CCAO V.
Condition for which the medicinal product can be applied
Rayvow® is available as a film-coated tablet with 50 or 100 mg of lasmiditan. The medicinal product can be used in adults for the acute treatment of the headache phase of migraine attacks, with or without aura. In the treatment of migraine attacks, preference is given to paracetamol in a sufficiently high dosage. Second choice medicinal products with similar effectiveness but more side effects are NSAIDs (ibuprofen, naproxen). Oral triptans (sumatriptan, rizatriptan, zolmitriptan) are third choice medicinal products.
Recommendations from the National Health Care Institute
The National Health Care Institute advises the Ministry of Health, Welfare and Sport to include lasmiditan (Rayvow®) in List 1A in cluster 0N02CCAO V. The standard dose can be set at 100 mg per attack. Based on the criteria for interchangeability, the National Health Care Institute concluded that lasmiditan (Rayvow®) is interchangeable with the seven triptans in the existing GVS cluster 0N02CCAO V.
Medicine Reimbursement System (GVS)
Lasmiditan is an extramural drug. Extramural drugs are medicinal products for home use, available at the pharmacy on prescription from a physician. They will only be reimbursed from the basic health care package if they are listed in the GVS. The amount of the reimbursement depends on the list the product is on. Interchangeable medicinal products are clustered in List 1A. These may be subject to a reimbursement limit. Unique medicinal products are listed in List 1B. There is no reimbursement limit for these products. Additional conditions may apply for reimbursement. In that case, a medicinal product is also listed on List 2.
The Scientific Advisory Board (WAR) advises the National Health Care Institute about the assessment. Based on the assessment, the National Health Care Institute sends an advisory report to the Minister of Health, Welfare and Sport. The Minister makes the final decision whether or not to reimburse the medication from the basic health care package.